PKI 14-22 amide,myristoylated TFA, CAS No.201422-03-9, Inhibitor of protein kinase A

Features and benefits
    Item Number
    P287239
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    P287239-5mg
    5mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $159.90
    P287239-10mg
    10mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $269.90
    P287239-25mg
    25mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $539.90
    P287239-50mg
    50mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $899.90

    Cell-permeable protein kinase A inhibitor

    View related series
    protein kinase A Inhibitor

    Basic Description

    Product NamePKI 14-22 amide,myristoylated TFA, CAS No.201422-03-9
    GradeMoligand™
    Product Description

    PKI 14-22 amide,myristoylated is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion.

    Specifications & PurityMoligand™, ≥98%
    Biochemical and Physiological MechanismsCell-permeable version of protein kinase inhibitor PKI (14-22) amide. The non-myristoylated version inhibits protein kinase A (Ki= 36 nM), inhibits cell growth and induces apoptosis in human pancreatic cancer cells (PANC-1).
    SequenceGRTGRRNAI(Modifications: Gly-1 = Myr-Gly, Ile-9 = C-terminal amide)
    Action TypeINHIBITOR
    Mechanism of actionInhibitor of protein kinase A

    Associated Targets(Human)

    PRKAR1A Tbio cAMP-dependent protein kinase type I-alpha regulatory subunit (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    PRKAR2A Tchem cAMP-dependent protein kinase type II-alpha regulatory subunit (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    PRKACB Tchem cAMP-dependent protein kinase catalytic subunit beta (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    PRKACG Tchem cAMP-dependent protein kinase catalytic subunit gamma (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    PRKAR1B Tbio cAMP-dependent protein kinase type I-beta regulatory subunit (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    PRKAR2B Tchem cAMP-dependent protein kinase type II-beta regulatory subunit (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    PRKACA Tchem cAMP-dependent protein kinase catalytic subunit alpha (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    Storage TempStore at -20°C,Desiccated
    Shipped InIce chest + Ice pads
    CAS201422-03-9

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Find and download the COA for your product by matching the lot number on the packaging.

    4 results found

    Lot NumberCertificate TypeDateItem
    E2430217Certificate of AnalysisFeb 29, 2024 P287239
    E2430218Certificate of AnalysisFeb 29, 2024 P287239
    E2430219Certificate of AnalysisFeb 29, 2024 P287239
    E2430220Certificate of AnalysisFeb 29, 2024 P287239

    Genetic information

    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    Solution Calculators